Send PM
Followers 28
Posts 1014
Boards Moderated 0
Alias Born 03/10/2014


Re: SAMNOTSAMUEL post# 32944

Monday, 02/12/2018 2:00:15 PM

Monday, February 12, 2018 2:00:15 PM

Post# of 50121
Didn't you pump the whole ICC Trial as the make or break for DCTH? Company stated they expected to begin in March this it should become reality!

Based on a public offering price of $0.02 per share, we expect to receive net proceeds from the sale of the securities that we are offering to be approximately $4.4 million, after deduction of placement agent fees, and commissions and estimated expenses payable by us.
We intend to use the net proceeds from this offering (including any resulting from the exercise of the warrants, if any) for:
• the clinical and regulatory development of clinical studies, including the Phase 3 Ocular Melanoma liver metastases trial, a registration trial for intrahepatic cholangiocarcinoma, investigator initiated trials mCRC and pancreatic cancer metastatic to the liver, and European Union Commercial Registry;
• commercialization of our products,
• obtaining regulatory approvals;
• research;
• capital expenditures and development of joint ventures and licensing arrangements for our products;
• working capital; and
• the balance, if any, for other general corporate purposes.

This states the money will be to start the Phase 3 ICC Trial...of course with the SPA they already have with the FDA regarding design, timelines, number of required patients, etc...
Also states mCRC trials? Pancreatic cancers, and European commercializations?

Doesn't look that bad buddy!

In My Own Personal Opinion Of Course!

Day Range:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent DCTH News